

Form PTO-1449 JAN 18 2005 U.S. Department of Commerce
Patent and Trademark Office
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Application Number	10/618,179
Filing Date	July 11, 2003
First Named Inventor	Bernard F. Erlanger
Art Unit	1626
Examiner Name	G.M. Shameem
Attorney Docket No.	64081/JPH/AJM/MVM

[illegible][illegible]

EXAMINER SIGNATURE *Li XWJ*

DATE CONSIDERED

9/12/2005

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicant: Bernard F. Erlanger et al.
U.S. Serial No.: 10/618,179
Filed: July 11, 2003
Exhibit A

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Application Number	10/618,179
		Filing Date	July 11, 2003
		First Named Inventor	Bernard F. Erlanger
		Art Unit	1626
		Examiner Name	G.M. Shameem
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Attorney Docket No.	64081/JFW/AJM/MVM

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LW	4	Avrameas, A. et al. (1998) "Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules," <i>Proc. Natl. Acad. Sci. USA</i> 95: 5601-5606;	
	5	Awwad, M. et al. (1994) "Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions," <i>Cancer Immunol. Immunother.</i> 38: 23-30;	
	6	Braden, B.C. et al. (2000) "X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C ₆₀ ," <i>Proc. Natl. Acad. Sci. USA</i> 97: 12193-12197;	
	7	Buschle, M. et al. (1997) "Transloading of tumor antigen-derived peptides into antigen-presenting cells," <i>Proc. Natl. Acad. Sci. USA</i> 94: 3256-3261;	
	8	Chen, B.-X. et al. (1998) "Antigenicity of fullerenes: Antibodies specific for fullerenes and their characteristics," <i>Proc. Natl. Acad. Sci. USA</i> 95: 10809-10813;	
	9	Fawell, S. et al. (1994) "Tat-mediated delivery of heterologous proteins into cells," <i>Proc. Natl. Acad. Sci. USA</i> 91: 664-668;	
	10	Koren, E. et al. (1995) "Murine and human antibodies to native DNA that cross-react with the A and D SnRNP polypeptides cause direct injury of cultured kidney cells," <i>J. Immunol.</i> 154: 4857-4864;	
	11	Lewin, M. et al. (2000) "Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells," <i>Nature Biotechnology</i> 18: 410-414;	
	12	Lundberg, M. et al. (2001) "Is VP22 nuclear homing an artifact?," <i>Nature Biotechnology</i> 19: 713;	
	13	Ma, J. et al. (1991) "Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG," <i>Clin. Exp. Immunol.</i> 84: 83-91;	
	14	Mitchell, D.J. et al. (2000) "Polyarginine enters cells more efficiently than other polycationic homopolymers," <i>J. Peptide Res.</i> 56: 318-325;	
↓	15	Rodwell, J.D. et al. (1986) "Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations," <i>Proc. Natl. Acad. Sci. USA</i> 83: 2632-2636;	

EXAMINER
SIGNATURE

DATE CONSIDERED 9/12/05


*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Application Number	10/618,179
	Filing Date	July 11, 2003
	First Named Inventor	Bernard F. Erlanger
	Art Unit	1626
	Examiner Name	G.M. Shameem
	Attorney Docket No.	64081/JPH/AJM/MVM

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LW	16	Rothbard, J.B. et al. (2000) "Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation," <i>Nature Medicine</i> 6: 1253-1257;	
↓	17	Sutton, B.J. et al. (1983) "The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G," <i>Biochem. Soc. Trans.</i> 11: 130-132; and	
↓	18	Wender, P.A. et al. (2000) "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters," <i>Proc. Natl. Acad. Sci. USA</i> 97: 13003-13008.	

 EXAMINER
SIGNATURE



DATE CONSIDERED

9/12/05

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.